IP Library Granted Patent US 12,365,865
Granted Patent B2
US 12,365,865 · App. 17/050,608 · Granted Jul 22, 2025

Scalable clarification process for recombinant AAV production

Inventors: Claire G. Zhang (Rockville, MD); Shaojie Weng (Rockville, MD); Ya-Chen Chang (Rockville, MD); Franz M. Gerner (Rockville, MD)
Assignee: REGENXBIO INC.
C12M47/02B01D39/18B01D39/2068C12N15/86B01D2239/065C12N2750/14143C12N2750/14151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,365,865
App. No.
17/050,608
Granted
Jul 22, 2025
Kind
B2
Abstract

Provided herein are scalable methods for the clarification of a composition comprising recombinant Adeno-Associated Virus (rAAV) particles and an impurity.

Claims (19)

1. A method for the clarification of a feed containing recombinant adeno-associated virus (rAAV) particles and an impurity comprising: (a) providing a feed comprising a suspension cell culture; (b) pretreating the feed by adding salt to a final concentration between about 0.2 M and about 0.6 M; (c) applying the pretreated feed to a filter train comprising a primary depth filter connected to a secondary depth filter, wherein the outflow of the primary depth filter is connected to the inflow of the secondary depth filter; (d) applying a buffer comprising 200 mM salt to the filter train after step (c); and (e) recovering a filtrate comprising the rAAV particles, wherein (i) the impurity comprises cells or cellular debris, (i) the method separates the rAAV particles from the impurity without the use of centrifugation or tangential flow microfiltration prior to (a), (iii) the feed volume is between about 100 liters and about 3000 liters, and (iv) steps (c) and (d) are performed at a flux between about 175 L/m 2 /hr (LMH) and about 225 LMH.

2. The method of claim 1 , wherein the filter train further comprises a tertiary filter connected to the secondary depth filter, wherein the outflow of the secondary depth filter is connected to the inflow of the tertiary filter.

3. The method of claim 1 , wherein the primary depth filter comprises a porous depth filter media comprising at least 2 graded layers of non-woven fibers having a total thickness of about 0.3 cm to about 3 cm, and wherein each of the at least 2 graded layers of non-woven fibers have a nominal pore size rating more than about 40 μm.

4. The method of claim 1 , wherein the secondary depth filter comprises a media comprising a composite of cellulose and diatomaceous earth.

5. The method of claim 2 , wherein the tertiary filter comprises a sterilizing grade filter media.

6. The method of claim 1 , wherein the ratio of primary filter area to secondary filter area is between about 1:3 and about 3:1.

7. The method of claim 2 , wherein the ratio of primary filter area to tertiary filter area is between about 1:3 and about 3:1.

8. The method of claim 2 , wherein the ratio of primary filter area to secondary filter area to tertiary filter area ratio is within the range of about 0.3-3 to about 0.3-3 to about 0.2-5.

9. The method of claim 1 , wherein the suspension culture is comprises a culture of Human Embryonic Kidney 293 HEK293 cells.

10. The method of claim 1 , wherein the culture has a total cell density of between about 1×10 6 cells/ml and about 30×10 6 cells/ml.

11. The method of claim 1 , wherein the salt in step (b) is NaCl.

12. The method of claim 1 , wherein the rAAV particles comprise an AAV capsid protein from an AAV selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV-11, AAV-12, AAV-13, AAV-14, AAV-15 and AAV-16, AAV.rh8, AAV.rh10, AAV.rh20, AAV.rh39, AAV.Rh74, AAV.RHM4-1, AAV.hu37, AAV.Anc80, AAV.Anc80L65, AAV.7m8, AAV.PHP.B, AAV2.5, AAV2tYF, AAV3B, AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, AAV.HSC5, AAV.HSC6, AAV.HSC7, AAV.HSC8, AAV.HSC9, AAV.HSC10, AAV.HSC11, AAV.HSC12, AAV.HSC13, AAV.HSC14, AAV.HSC15, and AAV.HSC16.

13. The method of claim 12 , wherein the AAV capsid serotype is AAV-8 or AAV-9.

14. The method of claim 1 , wherein the feed volume is between about 500 liters and about 3000 liters.

15. A method for producing a composition comprising isolated recombinant adeno-associated virus (rAAV) particles from a feed comprising an impurity, comprising

(a) clarifying the feed according to the method of claim 1 , and

(b) isolating the rAAV particles from the filtrate by one or more of tangential flow filtration, affinity chromatography, size exclusion chromatography, ion exchange chromatography, and hydrophobic interaction chromatography.

16. The method of claim 15 , wherein the isolating the rAAV particles comprises a first tangential flow filtration, affinity chromatography, anion exchange chromatography, and a second tangential flow filtration.

17. The method of claim 1 , wherein the feed is not pretreated with a chemical flocculent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2020
From: ZHANG, CLAIRE G.; WENG, SHAOJIE; CHANG, YA-CHEN; GERNER, FRANZ M.
To: REGENXBIO INC.
Reel/Frame 054166/0049 →
Continuity (3)
Provisional Application 62664254 · Apr 29, 2018
Provisional Application 62671968 · May 15, 2018
Related Publication 20240254430A1 · Aug 1, 2024
References Cited (21)
US 6566118B1 · Atkinson · 2003 [cited by examiner]
US 11021689B2 · Brument · 2021 [cited by examiner]
US 11203740B2 · Brument · 2021 [cited by examiner]
US 20070172846A1 · Zhang · 2007 [cited by examiner]
US 20130012689A1 · Singh · 2013 [cited by examiner]
US 20160289633A1 · Yang · 2016 [cited by examiner]
US 20200224173A1 · Clement · 2020 [cited by examiner]
EP 3054007 · 2016 [cited by applicant]
WO 03097797 · 2003 [cited by applicant]
WO 2010148143 · 2010 [cited by applicant]
WO WO2010148143A1 · 2010 [cited by examiner]
WO 2011009613 · 2011 [cited by applicant]
WO WO2017100676A1 · 2017 [cited by examiner]
WO WO2018226887A1 · 2018 [cited by examiner]
Tomic, S., Besnard, L., Fürst, B., Reithmeier, R., Wichmann, R., Schelling, P., & Hakemeyer, C. (2015). Complete clarification solution for processing high density cell culture harvests. Separation and Purification Tech… [cited by examiner]
International Search Report and Written Opinion of the ISA for PCT/US2019/029539, mailed Aug. 13, 2019, 16 pages. [cited by applicant]
Felo et al., “Process cost and facility considerations in the selection of primary cell culture clarification technology”, Biotechnology Progress, vol. 29, No. 5, Jul. 11, 2013, pp. 1239-1245. [cited by applicant]
“Clarification of mammaliancell cultures by depth filtration”, Millipore Filtration, Separation & Preparation, Mar. 1, 2017, XP002792835, 2 pages. [cited by applicant]
Besnard et al., “Clarification of vaccines: An overview of filter based technology trends and best practices”, Biotechnology Advances, vol. 34, No. 1, Dec. 2, 2015, pp. 1-13. [cited by applicant]
Prashad et al., “Depth filtration: Cell clarification of bioreactor offloads”, Filtration and Separation, vol. 43, No. 7, Sep. 1, 2006, pp. 28-30. [cited by applicant]
Weng, “Development of a scalable AAV harvest clarification process”, Molecular Therapy, vol. 26, No. 5, May 1, 2018, 1 page. [cited by applicant]